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A B S T R A C T
Objectives: To analyze the prevalence of high-risk HPV (human papillomavirus) and genetic alterations in
nonmalignant tonsils.
Methods: We collected benign fresh tonsillar tissue specimens from 477 patients undergoing tonsillectomy be-
cause of chronic tonsillitis or tonsillar hypertrophy in 2012 (Group A, n = 237) and in 2015 (Group B, n = 240).
Luminex xMAP technique served to detect E6/E7 DNA from 16 different high-risk HPV types. Tonsillar DNA and
peripheral blood leukocyte DNA from the infected individuals were analyzed using Nimblegen SeqCap EZ
Comprehensive Cancer Design panel. The panel targets 578 different genes that are relevant in carcinogenesis.
HPV negative tonsillar specimens from age- and gender matched individuals were used as controls. All speci-
mens harboring high-risk HPV were analyzed using fluorescence in situ hybridization (FISH).
Results: Five of 477 (1.0%) patients tested positive for the following HPV types: HPV16 (two cases), HPV52 (one
case), HPV66 (one case), HPV52 and HPV68 (coinfection, one case). FISH analyses showed that the appearance
of HPV in specimens infected with HPV 16 was episomal. Benign tonsils infected with high-risk HPV harbored
mutations in EP300, NF1, PIK3CA, and RB1 which are considered relevant in the development of HPV-associated
head and neck squamous cell carcinoma (SCC).
Conclusions: The prevalence of high-risk HPV in nonmalignant tonsils is low. High-risk HPV positive tonsils
harbored mutations in genes that are commonly altered in HPV-associated head and neck SCC. The role of these
mutations in tonsillar carcinogenesis is an interesting target for future research.
Introduction
Head and neck squamous cell carcinoma (SCC) accounts for ap-
proximately 600,000 new cancer cases each year [1]. The main risk
factors are tobacco and alcohol use. In many developed countries,
however, the majority of newly diagnosed tonsillar SCCs are associated
with high-risk human papillomavirus (HPV) infection, predominantly
HPV type 16 [2,3]. Compared to individuals with HPV negative ton-
sillar SCC, those with HPV positive disease have better prognosis, and
they are often younger with no significant history of tobacco or alcohol
use [4–6].
It is unclear why some individuals with high-risk HPV infections
develop malignant disease, while others are able to clear the infection.
Considering the significant role of HPV in tonsillar SCC, it is interesting
that HPV infections in non-malignant tonsils are extremely rare. Benign
tonsillar specimens collected from nearly 4000 tonsillectomy patients in
the UK were all HPV negative [7]. Because HPV prevalence in non-
malignant tonsils is low, and the proportion of HPV positive malignant
tonsils is high, a presumption has been raised that nonmalignant tonsils
harboring high-risk HPV may have a high risk of progression to cancer.
Cytological brush samples and excisional biopsies are used to detect
precancerous lesion from the uterine cervix [8]. A similar precursor
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lesion, that could be detected and treated before cancer fully develops,
has not been characterized for HPV-associated tonsillar SCC.
HPV has two important oncogenes, E6 and E7, whose expression
may increase upon integration of HPV into chromosomal DNA. In HPV-
associated carcinogenesis viral E6 and E7 proteins inactivate the func-
tion of cellular p53 and retinoblastoma (Rb) tumor suppressors, re-
spectively, which leads to dysregulation of the cell cycle, inhibition of
apoptosis, and eventually genetic instability [9]. Molecular genetic
analyses of HPV positive and HPV negative head and neck SCCs have
revealed that both chromosomal and mutational profiles in these two
distinct cancer types are different. Compared to tobacco associated
head and neck SCC, the number of mutations in HPV positive SCC is
typically lower. HPV negative head and neck SCCs harbor mutations in
TP53, unlike HPV positive SCCs where TP53 gene is wild-type but viral
E6 protein degrades the protein product [10–15]. Massive parallel se-
quencing of 120 matched pairs of head and neck tumor/normal samples
showed enrichment of mutations in PIK3CA, MLL3, DDX3X, FGFR2/3,
NOTCH1, NF1, KRAS, and FBXW7 in HPV positive SCC [16]. In addition
to these genes, previous studies have detected alterations in ASXL3,
EP300, ZNF750, TTN, and SYNE1 [12,13,15,17]. Analysis of HPV ne-
gative head and neck SCC has shown enrichment for mutations in a
different set of genes: TP3, FAT1, CDKN2A, TTN, SYNE1, NOTCH1,
PIK3CA, and NSD1 [18].
Systematic detection of mutations in cancer-relevant genes has be-
come feasible due to development of cancer sequencing gene panels
[19]. When considering preventive measures or targeted molecular
cancer therapies for HPV-associated disease, understanding the mole-
cular events preceding carcinogenesis is crucial. Defining which age
groups have the highest prevalence of tonsillar HPV infection helps to
understand the sexual and non-sexual routes of HPV transmission as
well as the natural course of the infection. The specific morphological
changes and mutations preceding HPV-associated SCC are poorly un-
derstood. Finding a precursor for tonsillar HPV-associated cancer would
help in the early detection of cancer, and in identifying individuals with
an increased risk of malignancy, who would possibly benefit from
preventive measures such as HPV-vaccination.
The aim of this study was to determine the prevalence of high-risk
HPV in nonmalignant tonsils, and to compare the prevalence rates be-
tween two study groups undergoing tonsillectomy in 2012 and in 2015.
Furthermore, genetic alterations in tonsils harboring high-risk HPV
infection were analyzed using a cancer gene panel.
Patients and methods
Study design
The study involved a total of 477 patients (median age 20.3, range
1.7–69.5 years) undergoing tonsillectomy because of tonsillar hyper-
trophy or chronic tonsillitis in Helsinki University Hospital, Department
of Otorhinolaryngology – Head and Neck Surgery. Of the 477 patients,
237 (49.7%) were recruited consecutively between August and
December 2012 (Group A), and 240 (50.3%) between April and
September 2015 (Group B). During both study periods the patients were
recruited in a similar consecutive manner on the day of operation.
Collecting samples in two separate time periods enabled us to evaluate
whether the prevalence of tonsillar high-risk HPV infection remained
stable from 2012 to 2015 in Helsinki capital area, comprising a popu-
lation of roughly 1 million. Demographics of the study participants are
presented in Table 1. The Ethics Committee of Surgery in the Hospital
District of Helsinki and Uusimaa approved the study protocol, and all
patients gave their informed written consent.
Collection of samples
One tonsil from each patient was individually processed for study
purposes using sterile equipment. One half was fixed, embedded in
paraffin and examined using standard haematoxylin eosin staining
sections to confirm benign non-neoplastic tonsillar histology without
dysplasia. The other half was divided into small pieces and stored fresh
either in Eppendorf tubes or phosphate-buffered saline at −80 °C until
analyses. Peripheral blood samples were drawn from each patient to
obtain genomic DNA from isolated blood leukocytes.
Tonsillar HPV PCR analyses
A clinical diagnostic laboratory in Tartu, Estonia (Quattromed HTI,
currently merged with Synlab Lab Services corporation) analyzed all
tonsillar fresh tissue specimens for high-risk HPV. Each specimen was
suspended in a lysis buffer containing 200 µl Magna Pure Bacteria Lysis
Buffer (Roche diagnostics, GmbH Mannheim, Germany) and 20 µl of
20 mg/ml Proteinase K (Thermo Scientific, MA, USA) and incubated for
24 h at +37 °C. DNA extraction was completed with MagNA Pure 96
DNA and Viral NA Small Volume Kit (Roche diagnostics, GmbH
Mannheim, Germany). Ten µl of the extracted DNA was used in PCR
amplification. In each sample, beta-globin gene amplification con-
firmed DNA integrity. Luminex xMAP platform was used to detect 16
different high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 68, and 82. The assay comprised 12 pairs of primers of
which four pairs are shared with different genotypes. One µl of the PCR
product from each specimen was mixed together with Luminex beads,
followed by hybridization at 95 °C for five minutes, and thereafter
cooling down to 55 °C for 15 min to hybridize single stranded DNA
products to HPV type specific oligonucleotides. Luminex MAGPIX in-
strument was used to detect high-risk HPV positivity.
Extracted DNA from Group A samples also underwent HPV 16
specific PCR analyses. Each 25 μl reaction contained 1x GeneAmp® PCR
Buffer I containing 15 mM MgCl2 (Thermo Fisher Scientific, Waltham,
MA, USA), 0.2 mM of each dNTP, 0.2 μM HPV16.S2 forward primer
(sequence: CAA CAA ACC GTT GTG TGA TT), 0.2 μM HPV.CTC reverse
primer (sequence: ATC TAT TTC ATC CTC CTC CTC T), 0.625 U of
AmpliTaq Gold® DNA Polymerase (Thermo Fisher Scientific) and 25 ng
Table 1
Demographic data and tonsillar high-risk HPV status in patients undergoing tonsillectomy







Number of patients 237 (49.7) 240 (50.3) 477 (100)
Gender
Male 92 (39) 90 (38) 182 (38)
Female 145 (61) 150 (63) 295 (62)
Age distribution (y)
< 7 Preschool children 42 (18) 63 (26) 105 (22)
7–16 School children 45 (19) 36 (15) 81 (17)
17–25 Young adults 65 (27) 66 (28) 131 (27)
26–40 Midlife adults 63 (27) 56 (23) 119 (25)
> 41 Older adults 22 (9) 19 (8) 41 (9)
HPV vaccination
Yes 6 (3) 20 (8) 26 (5)
No 231 (97) 220 (92) 451 (95)
Smoking
Never 153 (65) 160 (67) 313 (66)
Previous smoker
< 20 pack-years 33 (14) 24 (10) 57 (12)
Previous smoker
Over 20 pack-years 0 (0) 1 (0.4) 1 (0.2)
Current smoker
< 20 pack-years 48 (20) 51 (21) 99 (21)
Current smoker
Over 20 pack-years 3 (1) 4 (2) 7 (1)
High-risk HPV
Negative 235 (99.2) 237 (98.8) 472 (99.0)
Positive 2 (0.8) 3 (1.3) 5 (1.0)
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of the extracted DNA. The reactions were amplified in DNA Engine
Tetrad® 2 Peltier Thermal Cycler (BioRad, Hercules, CA, USA) using the
following conditions: Denaturation in 95 °C for 10 min followed by 40
cycles of 1 min at 95 °C, 1 min at 52 °C and 1 min at 72 °C, followed by
a final extension of 10 min at 72 °C, after which the reactions were
cooled down to 4 °C.
Fluorescence in situ hybridization (FISH)
All specimens harboring high-risk HPV, detected by PCR, were
subsequently analyzed by FISH. Positive controls included hybridiza-
tions on HPV 16 positive tissue from human uterine cervical in-
traepithelial neoplasia lesions. Negative controls were nonmalignant
tonsillar specimens without HPV 16, as determined by PCR. HPV FISH
was performed on 4 µm-thick tissue sections as described previously
[3,4]. Briefly, sections were pretreated pretreated with 85% formic
acid/0.3% H2O2, 1 M NaSCN and 4 mg/ml pepsine and hybridized
with a digoxigenin-labeled HPV 16-specific probe (PanPath, Budel, The
Netherlands) according to the manufacturer’s instructions. After strin-
gent washing in 50% formamide, 2xSSC, pH 7.0 at 42 °C (two times
5 min), probe hybridization was visualized by subsequent incubations
with mouse anti-digoxin (Sigma), peroxidase-conjugated rabbit anti-
mouse IgG, peroxidase-conjugated swine anti-rabbit IgG (both DAKO
A/S) and finally rhodamine-labeled tyramide. Preparations were
mounted in Vectashield (Vector Laboratories, Burlingame, CA) con-
taining 4,6-diamidino-2-phenyl indole (DAPI; Sigma: 0.2 g/ml). The
slides were then examined with the Leica DM5000B microscope with
appropriate fluorochrome filter sets.
Evaluation of nuclear hybridization signals was performed by two
investigators (AH and EJMS) according to previously described criteria
[3,4]: diffuse, dotted-like signals indicate episomal HPV DNA and nu-
clear punctate signals were considered to indicate integrated HPV DNA.
p16INK4A immunohistochemistry
Tonsillar specimens from high-risk HPV positive patients and from
their age- and gender matched controls were subjected to im-
munostaining using p16INK4A CINtec ready-to-use antibody (CINtech®
Histology Kit, Roche, Germany). Study pathologist (JH) carefully
evaluated the stained sections, blinded to the HPV-status.
Immunostaining for p16INK4A was graded as negative, weak, moderate,
or strong. Immunostaining for epithelial cells and germinal center
dendritic cells was analyzed separately.
Detection of cancer gene mutations in patients harboring tonsillar high-risk
HPV
A total of 10 tonsillar specimens, including five from patients har-
boring high-risk HPV infection and five from their age- and gender
matched controls, were analyzed at Functional Genomics Unit (FuGU),
Biomedicum Helsinki. To examine whether similar cancer gene muta-
tions were present in tonsils and leukocytes, peripheral blood leuko-
cytes from five high-risk HPV positive patients and two HPV negative
controls underwent similar analyses. DNA was extracted using
NucleoSpin kit (Macherey-Nagel, Düren, Germany) according to the
manufacturer’s recommendation. The samples were sequenced with
Illumina MiSeq sequencer (Illumina, San Diego, CA, USA) in one lane/
run using Roche Nimblegen SeqCap EZ, Comprehensive Cancer Design
panel (Roche Nimblegen, Basel, Switzerland). The target size of the
panel is 4 Mb and it targets 578 genes involved in different types of
cancers. Sequencing was performed as paired end sequencing for read
length 75 bp (PE75 or 2X75). The sequencing coverage across targeted
bases was 200x and the target bases above 20x coverage were included
in the analyses. The cut-off value for sequence variants was 2.5%
Results
Tonsillar high-risk HPV prevalence
Tonsillar high-risk HPV was detected by Luminex in 2 of 237 (0.8%)
patients in group A, and in 3 of 240 (1.3%) patients in group B. HPV 16
specific PCR analyses found no additional positive samples in group A.
Of five HPV positive patients, two males and two females were young
adults, and one male was 14 years old. None of them had been vacci-
nated against HPV. Two patients were positive for HPV 16 and one for
HPV 52. Two patients presented with weak HPV positivity: one for HPV
52, and the other for both HPV 52 and HPV 66. One patient with high-
risk tonsillar HPV infection, a 20-year-old female (patient 452), had
recurrent migraine type headaches, while all others presented with
insignificant medical history. Clinical data on HPV positive patients are
presented in Table 2.
Fluorescence in situ hybridization (FISH)
Tonsillar specimens that were PCR positive for HPV 16 were also
positive in HPV 16 specific FISH analyses, with episomal appearance
(Fig. 1). Specimens presenting with HPV 52 and HPV 66 in PCR ana-
lyses were FISH negative.
p16INK4A immunostaining
All HPV positive tonsillar specimens and their matched controls
were positive for p16INK4A. Immunohistochemical staining for p16INK4A
in the crypt epithelium was strong in 4 of 5 (80%) specimens harboring
high-risk HPV, whereas all HPV negative control specimens presented
with either moderate or weak immunostaining. Germinal center den-
dritic cells presented with moderate p16INK4A staining in two specimens
harboring HPV, while three HPV positive specimens and all controls
presented with weak staining.
Cancer gene mutations in tonsils harboring high-risk HPV
To explore mutations potentially associated with high-risk HPV in-
fection, we considered mutations that were present only in high-risk
HPV positive tonsils, but not in the corresponding peripheral blood
leukocytes of the same patients, or in HPV negative control tonsils. The
Table 2
Characteristics of 5 patients with tonsillar high-risk HPV infection.
Patient ID Age (y) Gender HPV type p16 IHC epithelium Smoking Indication for tonsillectomy
9 20 Male 52 +++ Never Chronic tonsillitis
239 14 Male 16 +++ Never Hypertrophy
429 21 Male 66 +++ Current smoker
< 10 pack-years
Chronic tonsillitis
452 20 Female 16 + Previous smoker
< 10 pack-years
Chronic tonsillitis
487 20 Female 52 and 68 +++ Never Chronic tonsillitis
Abbreviations: HPV, human papillomavirus; IHC, immunohistochemistry; +, weak staining; +++, strong staining.
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specific mutations present in at least two HPV positive tonsillar speci-
mens (n = 21) are presented in Table 3. These included EP300, NF1,
PIK3CA, and RB1 which, according to the previous studies, have shown
enrichment of mutations in HPV positive head and neck SCC [18]. All
exonic mutations presented in Table 3 were located either in the 3′
untranslated region (UTR) or in splice sites. Therefore, none of the
mutations resulted in amino acid substitutions. Mutations were not
detected in MLL3, FGFR2/3, NOTCH1, KRAS, or in FBXW7, which are
considered to play a significant role in HPV-associated head and neck
SCC. Some genes that may be relevant in HPV-associated carcinogenesis
(DDX3X, ASXL3, ZNF750, TTN, and SYNE1) were not included in the
Nimblegen SeqCap EZ Comprehensive Cancer Design panel. One male
patient (patient 239) presented with a homologous mutation in SSX1
gene, which is associated with an increased risk for synovial sarcoma
[20]. This mutation was detected in both tonsillar DNA and peripheral
blood leukocytes, and it is not likely to be associated with tonsillar HPV
infection.
We also analyzed mutations that were present in two HPV negative
tonsils, but not in the corresponding control leukocytes. These included
mutations in KRAS, FBXW7, EP300, RB1, and NF1. Thus, also HPV
negative tonsils harbored mutations in genes that, according to the
literature, are considered relevant in HPV carcinogenesis. However,
Fig. 1. Fluorescence in situ images A. Positive control from uterine cervical intraepithelial neoplasia lesion with episomal appearance. B. HPV negative tonsil. C HPV 16 positive tonsil
(patient 452) with episomal appearance D. HPV 16 positive tonsil (patient 239) with episomal appearance.
Table 3
Specific heterozygous, damaging mutations only present in ≥2 HPV positive tonsillar specimens, but absent in the patient leukocytes and in tonsillar specimens from HPV negative
controls.
Gene Patients (ID) Variant Chromosome Coordinate Exonic Percentage of altered reads
BAGE2 429, 452 A > A/G 21 11029721 Yes 22
BAGE2 429, 452 A > A/G 21 11047334 No 44
BCL10 9, 429 C > C/CA, CAA > CAA/C 1 85732559 Yes 38
BCL10 9, 452 G > G/A 1 85732582 Yes 55
CDKN2B-AS1,CDKN2B 9, 429 A > A/G 9 22005920 Yes 27
COL1A1 9, 452, 487 C > C/CA, CA > CA/C, CAA > CAA/C 17 48261836 Yes 39
EP300 239, 487 A > A/C 22 41575892 Yes 34
ETV6 239, 487 T > T/TA 12 11905742 No 20
FOXP1 9, 239 C > C/CT 3 71007462 Yes 17
IKZF1 9, 429 G > G/GT 7 50444181 No 17
MAF 9, 239 AAC > AAC/A 16 79632187 Yes 11
MAP2K2 9, 429 G > G/A 19 4097234 No 22
NF1 429, 452 C > C/CT, CT > CT/C 17 29575849 No 19
PIK3CA 429,487 C > C/CT, CT > CT/C 3 178917762 No 37
PTCH1 9, 239, 429 GAA > GAA/G, GA > GA/G 9 98245692 No 41
RB1 9, 452 G > G/T 13 49039122 Yes 21
RUNX1 452, 487 C > C/CT, CT > CT/C 21 36265323 No 26
SEPT6 429, 487 T > T/TA X 118752506 Yes 19
STIL 9, 487 T > T/G 1 47749582 No 63
TPR 452, 487 TA > TA/T, T > T/TA 1 186300535 No 18
WDR36 9, 452 GT > GT/G 5 110463621 Yes 46
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also HPV positive tonsils frequently harbored mutations in these spe-
cific locations.
Discussion
In this study, only 5 out of 477 (1%) patients undergoing tonsil-
lectomy because of chronic tonsillitis or tonsillar hypertrophy harbored
high-risk HPV in tonsils, and the prevalence was similar in 2012 and
2015. In a previous study conducted at Helsinki University Hospital,
benign tonsillar specimens were collected consecutively from tonsil-
lectomy patients in 2001 and 2002. In that study, tonsillar HPV was
detected from fresh tissue specimens using consensus-primer PCR in
6.3% (13 of 206) of patients. Only oncogenic HPV 16 was detected, and
11 of the 13 HPV positive cases presented either in children or in young
adults aged<26 years [21].
The prevalence of high-risk HPV infections is likely to decrease in
Finland because bivalent HPV vaccination was included in the Finnish
national vaccination program in November 2013. We showed, however,
that the prevalence of tonsillar HPV infection decreased already be-
tween 2002 and 2012. The difference may be partly explained by dif-
ferent methodologies, but otherwise the reason for this is unclear. HPV
etiology has not been implicated in tonsillar hypertrophy or chronic
tonsillitis. Therefore, HPV prevalence among patients undergoing ton-
sillectomy is likely to reflect the overall prevalence in the general po-
pulation.
The annual age-adjusted incidence of oropharyngeal cancer in the
Finnish population, per 100,000, is 2.3 in males and 0.8 in females.
Even if the prevalence of tonsillar high-risk HPV infection is ≤1%
(1000 per 100,000 or less) a small fraction of the infected individuals
will ultimately develop oropharyngeal HPV-associated cancer. In the
present study, altogether 160 of our 477 patients (34%) were midlife
adults or older. Interestingly, HPV was detected only in younger sub-
jects, and not in the older age groups where HPV-associated pre-
malignant findings might be expected.
The incidence of cervical HPV infection peaks soon after sexual
debut at 20–24 years of age, and decreases thereafter [22]. The in-
cidence of oral HPV infection appears to be more stable through all age
groups [23]. Oral and oropharyngeal HPV infections are likely to have
both sexual and non-sexual routes of transmission [24]. A high number
of lifetime sexual partners is associated with an increased risk for or-
opharyngeal SCC [25]. However, the association between sexual be-
havior and presence of HPV in benign tonsils is unclear. In the present
study, the majority (4 of 5) of the infected were young adults, who
possibly harbored recent sexually transmitted infections. Previous stu-
dies, however, have found tonsillar HPV infections also in children
[21,26]. HPV transmission can occur already before birth from mother
to child, or horizontally during infancy and childhood, possibly through
saliva or other routes [24].
Our study is consistent with the previous literature in that the
prevalence of tonsillar high-risk HPV infection in cancer-free patients is
low. Palmer and colleagues found HPV DNA neither in a material of
3377 formalin-fixed paraffin-embedded tonsils, nor in 511 homo-
genized fresh tonsil specimens, collected between 2004 and 2008 in the
UK. The authors concluded that, contrary to cervical high-risk HPV
infections, a high proportion of tonsillar high-risk HPV infections may
progress to cancer [7]. Other previous studies, some of which have
included only either children or adults, have reported tonsillar HPV
prevalence rates from 0 to 12% [27–34]. Kim et al. found HPV in 8 of
69 (12%) tonsillar samples collected from patients with chronic ton-
sillitis. In that study, real-time PCR was used to analyze whether HPV
DNA was episomal or integrated. E2/E6 ratio in three HPV 16 positive
tonsils showed purely episomal forms [29].
Previous studies have not reported HPV positivity in benign ton-
sillar specimens with in situ hybridization. Klingenberg et al. found
high-risk HPV by PCR in 2 of 195 (1%) non-malignant tonsils. However
FISH analysis was unable to detect oncogenic HPV 16 and 18 in the
PCR-positive specimens [31].
Possibly due to its porous structure and the lack of structural in-
tegrity, tonsillar reticulated squamous epithelium is more vulnerable to
HPV infection than other anatomical sites of the upper aerodigestive
tract. In HPV positive tonsillar SCC, patients typically have neck lymph
node metastases at presentation, although the primary tumor is often
small [4,6]. Rietbergen et al. showed that in specimens from 20 patients
with HPV positive oropharyngeal SCC, tumor-free resection margins
were all negative for HPV16 E6 mRNA [35]. Franceschi et al. showed
that deep brushing of 200 non-pediatric tonsils, three of which (1.5%)
were HPV positive, was an unsatisfactory method for non-invasive de-
tection of tonsillar precancerous lesions; the cytology slides were of
poor quality and those suspected of having atypical cells did not show
dysplasia in the formalin-fixed paraffin-embedded tissue blocks [36].
The low detection rate of HPV infections in benign tonsils, and the
difficulty in identifying premalignant lesions analogous to cervical in-
traepithelial neoplasia, may be explained by the HPV infection being
restricted to an extremely small area, possibly deep in the tonsillar
crypts. However, FISH analyses in a study by Mooren et al. showed that
dysplastic epithelium adjacent to HPV positive tonsillar SCC had posi-
tive punctate HPV pattern, indicating viral integration [37]. Dysplastic
tonsillar epithelium with integrated high-risk HPV may be a precursor
lesion in tonsillar carcinogenesis. In the present study, FISH analyses
showed episomal appearance of HPV 16 without dysplasia. To our
knowledge, this is the first study reporting high-risk HPV positivity by
FISH in benign tonsils.
In this study, we chose a comprehensive cancer gene panel to ex-
plore genetic alterations associated with high-risk HPV infection. High-
risk HPV positive tonsils harbored mutations in EP300, NF1, PIK3CA,
RICTOR, and RB1. In a recent study by Chung et al. these five genes
were among the 30 most commonly altered genes in HPV positive head
and neck SCC. The study evaluated genomic alterations of head and
neck SCC using FFPE specimens which included 84 from HPV positive
tumors [38]. The results were in line with the previous studies in that
PIK3CA was the most commonly altered gene in HPV positive tumors
[15]. Whether the mutations in EP300, NF1, PIK3CA, RICTOR, and RB1
are associated with high-risk HPV infections cannot be verified in our
material since the number of HPV positive samples was low. Mutations
in NF1 and PIK3CA were intronic, and the relevance of these specific
mutations in tonsillar SCC is unclear. However, malignancy-driving
mutations can occur in all genetic elements outside the coding region,
also in enhancer, silencer, insulator as well as in 5′UTR and 3′UTR [39].
In our material, also HPV negative tonsils harbored mutations in genes
that are considered relevant in HPV carcinogenesis. These specific lo-
cations frequently harbored mutations also in HPV positive tonsils.
Potentially, some mutations do not promote tumorigenesis in HPV ne-
gative tissue where p53 and Rb function normally, but are significant
with high-risk HPV infection when the functions of p53 and Rb are
inactivated. In the present study, a low cut-off value of 2.5% was set for
sequence variants, since only a small proportion of benign cells may
harbor HPV-associated genetic alterations. Therefore, mutations pre-
sent at low numbers could be missed when using a high cut-off value.
In four of five tonsils with high-risk HPV infection p16INK4A im-
munostaining was strong. In tonsillar SCC p16INK4A is used as a surro-
gate marker for HPV-association [40]. Our findings are in line with the
previous studies in that HPV negative benign tonsils often show positive
p16INK4A immunostaining [31]. Although p16INK4A immunostaining
was more pronounced in our high-risk HPV positive specimens, and also
observed in germinal center dendritic cells, the presence or specific
location of high-risk HPV cannot be analyzed by using p16INK4A im-
munohistochemistry.
Conclusion
The prevalence of high-risk HPV in nonmalignant tonsils was only
1%. FISH analysis showed that the appearance of HPV 16 was episomal.
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High-risk HPV positive tonsils harbored mutations in genes that are
commonly altered in HPV-associated head and neck SCC: EP300, NF1,
PIK3CA, RICTOR, and RB1. However, due to the low rate of HPV po-
sitive tonsils and the absence of tonsillar precancerous lesions, the in-
volvement of these mutations in HPV-associated carcinogenesis re-
quires further research.
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